Sanofi Tightens Grip on RSV with $1.15B Upfront Acquisition of Vicebio, Diversifying Beyond mRNA Vaccines

Sanofi; Vicebio; acquisition; RSV; human metapneumovirus; combination vaccine; Molecular Clamp technology; non-mRNA vaccine; vaccine pipeline; respiratory vaccines

FDA Approves Humacyte’s Symvess: A Revolutionary Off-the-Shelf Artery Implant for Vascular Trauma Repair

FDA Approval, Humacyte, Symvess, Vascular Trauma, Off-the-Shelf Artery Implant, Bioengineered Human Tissue, Extremity Vascular Trauma Treatment

AOA’s ‘Eye Deserve More’ Campaign Highlights the Unmatched Capabilities of the Human Eye

American Optometric Association, Eye Deserve More, The Eye, Human Eye, Eye Health, Comprehensive Eye Care, Digital Eye Strain, Vision Loss, Optometry